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Abstract
Background: Non-adherence to anti tuberculosis treatment is one of the crucial challenges in improving tuberculosis cure-
rates and reducing further healthcare costs. The poor adherence to anti-tuberculosis treatment among patients with
tuberculosis is a major problem in Ethiopia. Hence, this study assessed level of non-adherence to anti-tuberculosis therapy
and associated factors among patients with tuberculosis in northwest Ethiopia.
Methods: An institution based cross-sectional survey was conducted among tuberculosis patients who were following anti-
tuberculosis treatment in North Gondar zone from February 20 – March 30, 2013. Data were collected by trained data
collectors using a structured and pre-tested questionnaire. Data were entered to EPI INFO version 3.5.3 and analyzed using
statistical package for social sciences (SPSS) version 20. Multiple logistic regressions were fitted to identify associations and
to control potential confounding variables. Odds ratio (OR) with 95% confidence interval was calculated and p-values,0.05
were considered statistically significant.
Results: A total of 280 tuberculosis patients were interviewed; 55.7% were males and nearly three quarters (72.5%) were
urban dwellers. The overall non-adherence for the last one month and the last four days before the survey were 10% and
13.6% respectively. Non-adherence was high if the patients had forgetfulness (AOR 7.04, 95% CI 1.40–35.13), is on the
continuation phase of chemotherapy (AOR: 6.95, 95% CI 1.81–26.73), had symptoms of tuberculosis during the interview
(AOR: 4.29, 95% CI 1.53–12.03), and had co-infection with HIV (AOR: 4.06, 95% CI 1.70–9.70).
Conclusions: Non-adherence to anti-tuberculosis treatment was high. Forgetfulness, being in the continuation phases of
chemotherapy, having symptoms of tuberculosis during the interview, and co-infected with HIV were significantly
associated with non-adherence to anti-tuberculosis therapy. Special attention on adherence counseling should be given to
symptomatic patients, TB/HIV co-infected patients, and those in the continuation phase of the tuberculosis therapy.
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Introduction
Tuberculosis (TB), one of the oldest diseases known to affect
humans, is a major cause of death worldwide. It usually affects the
lungs, although other organs are involved in up to one-third of the
cases. If left untreated, 50–65% of TB cases will die within 5 years
[1]. In 2010, there were 8.8 million new cases of TB and 1.45
million deaths from TB worldwide. The human immunodeficiency
virus (HIV) pandemic presents a significant challenge to global TB
control. TB is the second leading cause of death from an infectious
disease worldwide among all people and the leading preventable
cause of death among people living with HIV. About 13% of TB
cases occur among people living with HIV [2,3].
According to recent estimates, Ethiopia stands 7th in the list of
high TB burden countries. In Ethiopia, TB is the leading cause of
morbidity, the third cause of hospital admission, and the second
cause of death. The estimated TB incidence in Ethiopia was 261/
100,000 inhabitants in 2011. The lifetime risk of developing TB in
Ethiopia is estimated to be 50–60% for HIV-infected people, only
10% for HIV-negative counterparts [3,4].
Poor adherence to treatment of chronic diseases including TB is
a worldwide problem of striking magnitude [5]. However, patients
with TB are expected to have adherence levels greater than 90%
in order to facilitate cure [6,7]. The failure for cure increases the
risk of development of drug resistant strains and further spread of
TB in the community, which in turn increases morbidity and
mortality. Adherence to TB treatment is crucial to achieve cure
and avoid emergence of drug resistance [7]. In sub Saharan
Africa, there is high rate of losses to follow up of TB patients that
ranged from 11.3% to 29.6% [8]. Ethiopia is one of the seven
countries that reported lower rates of treatment success (84%) [3].
Patients who take their TB treatment in an irregular and
unreliable way are at greatly increased risk of treatment failure,
relapse and the development of drug-resistant TB strains.
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e78791
Furthermore, the emergence and spread of multi drug resistant
(MDR) and extensive drug resistant (XDR) TB further reinforces
the absolute necessity of helping TB patients to not miss any doses
of anti TB [9,10]. However, it is very difficult to have regular
supervision and support of TB patients in developing countries like
Ethiopia. Hence, this study assessed the level of non-adherence to




The study was conducted in the North Gondar zone, northwest
Ethiopia. The zone has 22 districts with a total population of
2,921,470. All health facilities providing anti-TB services in three
major towns of north Gondar (Gondar, Metema and Debark) were
included. Newly diagnosed TB patients receive six months of
standard TB chemotherapy in two phases- an intensive phase for
two months and a continuation phase of four months. A fixed dose
combination of RHZE (Rifampicin, Isoniazid, Pirazinamide and
Ethambutol) is given in the intensive phase of anti-TB therapy
while only RH during the continuation phase. Patients collect anti-
TB drugs daily during the intensive phase except weekends while
weekly or monthly during the continuation phase. Provider
initiated voluntary counseling and testing for HIV infection was
also offered currently to all TB patients.
Study Design and Participants
An institution based cross-sectional survey was conducted from
February 20 – March 30, 2013. Eligible patients were new TB
patients aged at least 15 years regardless of the site or the smear
status of their TB. To be eligible for this study, patients must have
also taken anti-TB at least for a month.
Sample Size and Sampling Procedures
The sample size was calculated using a single population
proportion formula; considering 21% proportion of non- adher-
ence level according to previous similar study from southwest
Ethiopia (16), a 5% margin of error, and 10% possible non-
response rate. The sample size was estimated to be 281. All adult
TB patients ($15 years old) on anti-TB at tuberculosis follow up
clinics in the three (Gondar, Metema and Dabark) towns within
the study period were interviewed.
Data Collection and Assessment of Non - adherence
Data were collected using an interviewer-administered ques-
tionnaire. The questionnaire was composed of socio-demographic
characteristics, patient related; therapy or drug related informa-
tion, social and health system /health provider related variables
and pre-tested before the actual data collection. Data were
collected after verbal informed consent was obtained. Six nurses
who were trained for this purpose collected the data. Data
collectors were also not part of the health facilities where TB
patients interviewed.
Recent non- adherence (last 4 days) and non-adherence during
the last one month before the survey were assessed. Patients were
asked to report the total number of anti-TB pills they missed 4
days before the survey. These numbers of pills were compared to
the number of pills prescribed to the patient. Adherence to TB
medication in the last 4 days was classified as non-adherent (missed
at least 1 (25%) of the pills prescribed over 4 days) and completely
adherent (no missed pill in the last 4 days before the survey).
Similarly, the last one month non-adherence was calculated as
total reported missed pills over the total prescribed pills within that
month and classified as adherent (no more than 10% of pills
missed) and otherwise non- adherent. Patients were also asked to
report why they missed anti-TB drugs. A patient who scores three
or more than three from a six item questions asked to measure TB
knowledge were considered to have good knowledge about TB.
These questions were obtained from information routinely
provided to patients as part of the national TB program.
Data Analysis
Data were entered to EPI INFO version 3.5.3 and analysis was
conducted using statistical package for social sciences (SPSS)
version 20. Descriptive statistics like frequencies and cross
tabulation were made for most selected variables. Multiple logistic
regression analysis was used to assess the association between the
dependent variable and each independent variable. Variables with
p-values #0.2 in bivariate analysis were fitted in the final multiple
logistic regression model to assess the strength of association and
control confounding effects. Both Crude Odds Ratio (COR) and
Adjusted Odds Ratio (AOR) with 95% confidence interval (CI)
were used to show an association between selected variables.
Variables having p-value #0.05 in the final model were taken as
significant determinants.
Ethical Considerations
The ethical clearance was obtained from the Institutional
Review Board of the University of Gondar. The Institutional
Table 1. Socio-demographic characteristics of respondents’,
North Gondar zone, Northwest Ethiopia, May 2013 (n = 280).
Characteristics Frequency Percent
Residence Urban 203 72.5
Rural 77 27.5
Sex Male 156 55.7
Female 124 44.3
Age (years) #32 171 61.1
.32 109 38.9




Education level No formal education 141 50.4
Primary level 85 30.4
Secondary level &above 54 19.3
Occupation Farmer 58 20.7
Merchant 48 17.1
Daily laborer 43 15.4
Housewife 48 17.1
Students 39 13.9
Government employee 17 6.1
Jobless 19 6.8
Others 8 2.9
Religion Orthodox 251 89.6
Muslim 29 10.4
Ethnicity Amhara 275 98.2
Tigrie 5 1.8
doi:10.1371/journal.pone.0078791.t001
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Review Board approved the oral informed consent since it was
anticipated that many of the study subjects could not read and
write. In addition to this, the Institutional Review Board approved
all ethical procedures, based on the awareness about the type of
study (that it was harmless to study subjects) and the education
level of study subjects. An official permission letter was obtained
from each health facility administration office. During data
collection, oral informed consent was obtained from all partici-
pants after they were introduced to the purpose of the study and
informed about their rights to interrupt the interview at any time.
To ensure confidentiality, names were avoided in the question-
naire and reporting the results of the study. In addition, the
collected information was locked with a key (hard copies) and by
passwords (soft copies). Informed oral consent was also obtained
from parents or guardians for subjects under 18 years old.
Results
Socio-demographic Characteristics
A total of 280 TB patients (with a response rate of 99.6%) were
interviewed. Nearly three quarters (72.5%) were urban dwellers
and had a mean age of 32.9 (614.8 SD) years. About half of them
(50.4%) did not attend any formal education and nearly one fifth
of them were farmers. Amhara (98.2%) and Orthodox Christianity
Figure 1. Reasons of anti-TB pills missing, North Gondar zone, Northwest Ethiopia, May 2013.
doi:10.1371/journal.pone.0078791.g001
Table 2. Healthcare system and other related characteristics of respondents’, North Gondar zone, Northwest Ethiopia, May 2013.
Characteristics Frequency Percent
Time to reach to the health facility #30 minutes 205 73.2
.30 minutes 75 26.8
Transportation On foot 266 95
Public transport 14 5.0
Waiting time in the health facilities #30 minutes 269 96.1
.30 minutes 11 3.9
Availability of drugs Always available 278 99.3
Not always available 2 0.7
Counseling Yes 204 72.9
No 76 27.1
Relationship with health workers Very friendly 152 54.3
Friendly 126 45.0
Unfriendly 2 0.7
TB status disclosure to the family Yes 272 97.1
No 8 2.9
Treatment supporter Health facility worker 166 59.3
Health extension worker 4 1.4
A family member 182 65
Religious leaders 10 3.6
No treatment supporter 22 7.9
Visited quacks Yes 36 12.9
No 244 87.1
Quacks are ‘Traditional healers’.
doi:10.1371/journal.pone.0078791.t002
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(89.6%) were the most common ethnicity and religion respectively
(Table 1).
Non-adherence to Anti-TB Treatment and Reasons of Pill
Missing
The overall calculated non-adherence over one month and the
last four days before the survey were 10% and 13.6% respectively.
Forgetfulness (34%), vomiting (24%) and traveling to other places
(17%) were the most frequent reasons for missing the anti-TB pills
(Figure 1).
Patient Related Characteristics
About 6% of TB patients reported that they had a problem of
forgetfulness. Almost all (98.9%) participants had good knowledge
about TB but 3.6% of participants reported they had stopped
taking their medication without telling their health care provider
because they felt worse when they took it. Similarly, 3.6% of
participants reported that they stopped taking their anti-TB
medication when they felt better. About 6% of participants were
substance users.
Healthcare System and Other Related Characteristics
Ninety five percent of TB patients walked to and from the
health facilities and 26.8% of participants reported that it took
them more than half an hour to reach the nearby health facility
providing them the anti-TB drugs. Nearly half of participants
(54.3%) reported that the health workers were very friendly to
them.
Most of TB patients (97.1%) in the current study disclosed their
illness to their relatives and most (75%) of those who had not
disclosed were due to fear of stigma. The rest had no relatives with
whom to share their problem. About one in eight (12.9%)
participants visited quacks (i.e. Traditional healers) while they
were taking their chemotherapy (Table 2).
TB Disease and Treatment Related Characteristics
A significant proportion of TB patients (38.9%) reported some
kind of anti-TB medication adverse effects. Three quarters (75.2%)
and 37% of participants complained of minor adverse effects such
as urine discolorations and headache or dizziness, respectively.
Most patients (87.5%) were naive for anti-TB medication. Almost
all (97.5%) of the TB patients were screened for HIV and nearly
one quarter (23.4%) of them were positive (Table 3).
Factors Associated with Non-adherence to Anti-TB
Treatment
In the bivariate analysis, forgetfulness, phases of chemotherapy,
symptoms of TB during the interview, HIV co-infection,
Table 3. Anti-TB therapy and diseases related characteristics of TB patients, North Gondar zone, Northwest Ethiopia, May 2013.
Characteristics Frequency Percent
Experience of side effects Yes 109 38.9
No 171 61.1
Types of side effects (n = 109) Skin rash 17 15.6
Headache & dizziness 42 36.7
Yellow eyes 13 11.9
Vomiting 32 29.4
Urine discoloration 82 75.2
Symptoms of TB during the interview Yes 36 12.9
No 244 87.1
Treatment category New 245 87.5
Re-treatment 35 12.5
Types of TB PTB-SM+ 116 41.4
PTB-SM2 97 34.7
EPTB 67 23.9
HIV screening status Screened 273 97.5
Not screened 7 2.5
HIV status (n = 273) Positive 64 23.4
Negative 209 76.6
ART status (n = 64) Started 44 68.8
Not started 20 31.2
OIs other than TB (n = 64) Yes 17 26.6
No 47 73.4
Drugs other than anti-TB & HAART (n) None 221 93.6
CPT 15 6.4
Phases of chemotherapy Intensive phase 86 30.7
Continuation phase 194 69.3
CPT = cotrimoxazole preventive therapy, EPTB = Extra pulmonary TB, PTB-SM+ = Smear positive pulmonary TB, PTB-SM2 = Smear negative pulmonary TB,
OI = Opportunistic Infections.
doi:10.1371/journal.pone.0078791.t003
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experience of drug side-effects, visiting quacks, and taking
additional drugs other than anti-TB were significantly associated
with anti-TB treatment non-adherence.
However, in the adjusted analysis, forgetfulness, phases of
chemotherapy, symptoms of TB during the interview and HIV co-
infection were remained significantly and independently associated
with anti-TB medication non-adherence. Those patients who had
a problem of forgetfulness were seven times more likely to be non-
adherent than their counterparts (AOR: 7.04, 95% CI 1.40–
35.13). TB patients who were in the continuation phases of
chemotherapy were seven times (AOR: 6.95, 95% CI 1.81–26.73)
more likely to be non-adherent to anti-TB medications. In
addition to this, patients who had symptoms of TB during the
interview (AOR: 4.29, 95% CI 1.53–12.03) and had co-infection
with HIV (AOR: 4.06, 95% CI 1.70–9.70) were also at higher risk
of non-adherence than those who were non-symptomatic during
the interview and HIV sero-negatives respectively (Table 4).
Discussion
Adherence to anti-TB treatment is a major determinant of
treatment outcome. In developing countries where inequities in
access to health care are high and health resources are scarce the
magnitude and impact of poor adherence is assumed to be higher.
It is undeniable that many patients experience difficulties in
following treatment recommendations [5,11]. Hence, this study
assessed the level and determinant factors of non-adherence to
anti-TB medications.
Though a self-reported level of non-adherence is assumed to be
under-estimated, a high proportion (10%) of non-adherence in the
last one month before the survey was found in this study. Similarly,
a higher proportion of non-adherence (13.6%) in the four days
prior to the survey was reported. This finding is more than twice
that reported from Kenya (4.8%).
However, the present non-adherence over one month was lower
than the previous reports from Southern Ethiopia (20.8%),
Uganda (25%), Kolkata, India (40.5%), and the Jiangsu Province
of China (12.2%) [12–15]. This is probably due to variations in
study populations. In this study we included both HIV-positive
and HIV-negative patients. The former studies included only TB-
HIV co-infected patients. HIV co-infected patients are much more
likely to be non-adherent for several reasons. On the other hand,
this variation may be attributable to the duration in which the
adherence was calculated. In the case of the Ugandan study,
adherence was estimated over the last five days and it was over the
whole intensive phase in the case of Kolkata India.
In the adjusted analysis; forgetfulness, being in continuation
phases of chemotherapy, having symptoms of TB during the
interview, and HIV co-infection were significantly associated with
anti-TB medication non-adherence. Those TB patients who were
in the continuation phase of the chemotherapy were about seven
times more likely to be non-adherent than those who were in the
intensive/directly observed treatment short-course strategy
(DOTS). However, it is believed that DOTS with daily supervision
is a difficult task for most patients and in particular HIV co-
infected patients who needed to attend the clinics for ART. It is
also believed that DOTS is too rigid a strategy [16]. Similar
findings were also reported from Southern Ethiopia, Brazil, and
Uganda, [13,17,18].
TB patients who were symptomatic during the interview were
much more likely to be non-adherent than those who did not have
symptoms of TB during the interview. Under normal circum-
stances patients whose TB symptoms were resolved quickly may be
urged to leave treatment once they started feeling better. However,
in this study the opposite was true. Patients may remain
symptomatic as a result of their poor adherence. On the other
hand, patients who remain symptomatic while sticking to
treatment may be disappointed and intentionally miss their pills.
However, a study conducted in Kolkata, India declared that the
urge to leave treatment once patient started feeling better was a
significant determinant of non-adherence to anti-TB medication
[14].
The proportion of HIV co-infection among TB patients was
23.4%. About 69% of these patients were on ART. In this study,
HIV co-infected TB patients were less likely to be adherent to their
anti-TB medications. HIV/AIDS co-infected patients have many
Table 4. Logistic regression analysis of factors associated with non- adherence to anti-TB (last 1 month).
Characteristics Non-adherence Crude OR Adjusted OR
Yes no (95% CI) (95% CI)
Forgetfulness Yes 4 7 5.83(1.59–21.36) 7.04(1.40–35.13)
No 24 245 1.00 1.00
Phases of Chemotherapy Intensive phase 3 87 1.00 1.00
Continuation phase 25 165 4.39(1.29–14.96) 6.95(1.81–26.73)
Symptoms of TB during the interview Yes 9 27 3.95(1.62–9.59) 4.29(1.53–12.03)
No 19 225 1.00 1.00
Visited quacks Yes 7 29 2.56(1.01–6.55)
No 21 223 1.00
Experience side effects Yes 17 92 2.69(1.21–5.99)
No 11 160 1.00
Co- infection with HIV Yes 14 50 3.90(1.75–8.71) 4.06(1.70–9.70)
No 14 195 1.00 1.00
Additional drugs Yes 9 38 2.67(1.12–6.34)
No 19 214 1.00
North Gondar zone, Northwest Ethiopia, May 2013.
doi:10.1371/journal.pone.0078791.t004
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pills to take and the adverse effects of anti-TB medication are more
common for HIV co-infected patients [7]. Similarly, HIV/AIDS
co-infected patients may be less motivated to take their medica-
tion. This phenomenon has been reported in Brazil, Kenya and
South Africa [18–20].
As previously reported from other studies [12,21], forgetfulness
was also an important problem associated with poor adherence to
anti-TB. This problem may be related to older age, as older age
was significantly associated with non- adherence over the last four
days. This might be also explained by HIV/AIDS related
encephalopathy or dementia.
However, previously confirmed factors like distance from a
health facility, transportation cost, relationship with health worker,
and proper counseling were not associated with non-adherence in
this study. Currently, in Ethiopia, TB treatment is being provided
freely at the community, grass root level. However, some patients
still questioned the accessibility of TB related services. Further-
more, most TB patients had good relationship with their health
care provider (99.3%). In general adherence is a dynamic issue
and barriers are also liable to change over time, which necessitates
continuation of multi-disciplinary collaborative researches. Finally,
this study shares the limitations of cross-sectional studies and hence
it might suffer from temporal relationship establishment with some
variables and might not provide much stronger evidence of
causality. In addition to this, this study only addressed a self-
reported level of non-adherence and it might be under-estimated.
Conclusions
Non-adherence among TB patients was high. Forgetfulness,
being in continuation phases of chemotherapy, having symptoms
of TB during the interview, and HIV co-infection were
significantly associated with anti-TB medication non-adherence.
Thus, special attention and adherence counseling should be given
for those who remained symptomatic, those who are co-infected
with HIV, and those in the continuation phase of the chemother-
apy. Further research is also recommended since the issue of
adherence is dynamic.
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